A Critical Evaluation of Octreotide Capsules in Acromegaly - New York City

New York, NY US

A regional CME opportunity to learn about options for the treatment of acromegaly including a new medical therapy, oral octreotide. Sponsored by the Endocrine Society, 30 Regional CME Dinner Events will be held in cities across the US, each dinner event will feature a one-hour CME presentation followed by discussion with an expert on treating patients with acromegaly.

Target Audience

The target audience for this educational content is endocrinologists, neurosurgeons, fellows, residents and allied healthcare providers.

Learning Objectives

As a result of participating in this activity, learners should be able to:

  • Explain efficacy and safety outcomes associated with control of GH/IGF-I levels and amelioration of signs/symptoms
  • Educate patients in successful and safe management of their disease using an oral therapeutic alternative
  • Understand and share latest clinical developments in oral treatment of patients with acromegaly

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Adrenal/HPA Axis
Quality Improvement and Healthcare Delivery
General Endocrinology
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
03/09/2016
Course expires: 
03/09/2017
Rating: 
0
Capital Grille
120 W 51st Street
Time Life Bldg
New York, NY 10020
United States

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Pamela Freda: Investigator and Speaker, Chiasma Inc.

The following SPC member who reviewed content for this activity reported no relevant financial relationships:
Larry Fox, MD

Endocrine Society and CMM Global staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/09/2016
Course expires: 
03/09/2017